Vijaya Diagnostic Centre Ltd.
NSE: VIJAYAVijaya Diagnostic Centre Ltd.: A 30-second snapshot
Vijaya Diagnostic Centre trades at Rs 1392.60, up 30.18% over the past year and 9.66% over three months, sitting 3.29% below its 52-week high and above both its 50-day (Rs 1342.38) and 200-day (Rs 1110.40) moving averages. Q1 FY27 results (quarter ended June 2026) showed revenue up 22.8% and consolidated net profit up 37.6% YoY to Rs 531M, alongside a trailing PE of 78.30 (forward 53.33) that is the richest among 6 tracked Pharma-sector peers. The company also disclosed a CFO resignation effective July 24, 2026, in the same reporting window.
P/E
78.3
Forward P/E
53.3
ROE
—
Debt / Equity
44.15
Profit Margin
+21.9%
Div. Yield
+0.1%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
72/100
News
8 headlines · 4 positive · 1 negative
VIJAYA: Q1 FY27 revenue up 22.8%, EBITDA up 34%, with robust expansion and strong margins - TradingView
TradingView
Vijaya Diagnostic Centre consolidated net profit rises 37.60% in the June 2026 quarter - business-standard.com
business-standard.com
VIJAYA: Q1 FY27 saw 22.8% revenue growth, margin expansion, and accelerated network rollout - TradingView
TradingView
Vijaya Diagnostic Centre Posts Q1 Consolidated Net Profit Of 531M Rupees Versus 383M Rupees YoY - Sahi
Sahi
Vijaya Diagnostic Centre CFO resigns effective July 24, 2026 - scanx.trade
scanx.trade
Recent context
- ·Q1 FY27 (quarter ended June 2026) results: revenue up 22.8% YoY, EBITDA up 34%, and consolidated net profit up 37.6% YoY to Rs 531M from Rs 383M, reported Aug 6-7, 2026 across TradingView, Business Standard and Sahi.
- ·CFO resignation effective July 24, 2026, reported by scanx.trade, ahead of the Q1 results announcement.
- ·News sentiment across 8 tracked headlines skewed positive (4 positive, 3 neutral, 1 negative), with an overall label of 'positive'.
Strengths
- +Q1 FY27 revenue grew 22.8% YoY with EBITDA up 34% and consolidated net profit up 37.6% YoY to Rs 531M from Rs 383M, per company results reported Aug 6-7, 2026.
- +Five-year revenue growth of 22.8% and earnings growth of 37.3%, with ROE above 15% in 4 of the last 5 tracked years and positive free cash flow in 4 of 5 years (consistencyScore 83).
- +Quality score of 57 ties atop the 6 tracked Pharma-sector names (peer range: Dr. Reddy's 4, Cipla 28, Max Healthcare 37, Apollo Hospitals 44, Sun Pharma 57).
- +Price trades above both the 50-day and 200-day moving averages, 3.29% off its 52-week high, with a neutral RSI of 57.32.
Weaknesses
- −Trailing PE of 78.30 (forward 53.33) is the richest among 6 tracked Pharma peers (range 30.31 to 70.51), ranking last (6 of 6) on the sector PE comparison.
- −CFO resignation effective July 24, 2026, disclosed in the same period as Q1 FY27 results.
- −Debt-to-equity trend is classified 'rising' in the multi-year persistence data, with the current level equivalent to roughly 0.44x.
- −ROE is reported as null in the fundamental dataset despite persistence data showing ROE above 15% in 4 of the last 5 years, and priceChange1Y is unavailable for all 5 sector peers, limiting relative comparison.
Open questions
- ?Does the CFO resignation reflect a planned transition or a response to internal issues, and who has been named as successor or interim finance lead?
- ?How does the rising debt-to-equity trend align with funding plans for continued diagnostic-center network expansion?
- ?Does the current PE of 78.30 (forward 53.33) -- the richest among tracked Pharma peers -- reflect the five-year earnings growth of 37.3%, or does it leave less room for multiple compression if growth normalizes?
- ?What explains the ROE data gap in the fundamental dataset given the underlying persistence metrics show ROE above 15% in 4 of the last 5 years?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| VIJAYA | Vijaya Diagnostic Centre Ltd.You're viewing | 78.3 | — | 57 |
| Industry avg | across 5 peers | 47.9 | +14.9% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 65.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 70.5 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 30.3 | +8.8% | 4 |
Technical state
Current price
₹1,392.60
SMA 50
₹1,342.38
SMA 200
₹1,110.40
RSI (14)
57.3 (neutral)
From 52w high
-3.3%
1Y return
+30.2%
3M return
+9.7%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumTrailing PE of 78.30 (forward PE 53.33) is the richest valuation among 6 tracked Pharma-sector names (range 30.31 Dr. Reddy's to 70.51 Max Healthcare); VIJAYA ranks last (6 of 6) on the sector PE ranking despite ranking 1st of 6 on quality score (57).
- lowDebt-to-equity trend is classified 'rising' in the multi-year persistence data. The current level (debtToEquity 44.15 on the dataset's percent scale, equivalent to roughly 0.44x) remains moderate, but the upward trend is worth tracking against funding for continued network expansion.
- mediumCFO resignation effective July 24, 2026 was reported by scanx.trade, a senior finance-leadership change disclosed in the same period as Q1 FY27 results.
- lowROE is reported as null in the fundamental keyMetrics block despite the persistence dataset showing ROE above 15% in 4 of the last 5 tracked years, and priceChange1Y is unavailable for all 5 sector peers, limiting relative-performance context.
Cross-section contradictions
- CFO resignation (effective July 24, 2026) and a rising debt-to-equity trend are governance and balance-sheet signals, yet the stock trades just 3.29% below its 52-week high, up 30.18% over 1 year and 9.66% over 3 months, and remains above both its 50-day (Rs 1342.38) and 200-day (Rs 1110.40) moving averages -- these signals have not coincided with price weakness.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 11 Aug 2026 · rotates through NIFTY 500 every ~5 days